Bio­gen prices new ALS drug at more than $14K per dose

Bio­gen has priced its new ALS drug Qal­sody at $14,230 per dose, a spokesper­son con­firmed to End­points News on Mon­day.

Qal­sody, al­so known as tofersen, won an ac­cel­er­at­ed ap­proval last week for a rare type of ALS marked by a mu­ta­tion called SOD1. On­ly about 1% or 2% of ALS pa­tients have the mu­ta­tion, rep­re­sent­ing about 300 peo­ple in the US, ac­cord­ing to Bio­gen.

At 14 dos­es the first year and 13 dos­es each year af­ter, Qal­sody amounts to more than $199,200 the first year and near­ly $185,000 in sub­se­quent years, a spokesper­son con­firmed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.